Role of nitric oxide in motor control: Implications for parkinson's disease pathophysiology and treatment

Current Pharmaceutical Design

Volumn 17, Issue 5, 2011, Pages 471-488

  Del Bel, Elaine ^a   Padovan Neto, Fernando Eduardo ^a   Raisman Vozari, Rita ^b,c,d   Lazzarini, Marcio ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

^b INSERM   (France)

^c SORBONNE UNIVERSITÉ   (France)

^d CNRS   (France)

Author keywords

7 nitroindazole; Abnormal involuntary movements; Dopamine; Dyskinesia; L dopa; Mice; Motor behaviour; Nitric oxide synthase inhibitor; Parkinson's disease

Indexed keywords

1H 1,2,4 OXADIAZOLO[4,3 A]QUINOXALIN 1 ONE; 7 NITROINDAZOLE; AMANTADINE; LEVODOPA; N(G) METHYLARGININE; N(G) NITROARGININE; N(G) NITROARGININE METHYL ESTER; NITRIC OXIDE; NITRIC OXIDE SYNTHASE INHIBITOR;

ARTICLE; DRUG EFFECT; DRUG MECHANISM; DYSKINESIA; HUMAN; MOTOR CONTROL; NONHUMAN; PARKINSON DISEASE; PATHOPHYSIOLOGY; PRIORITY JOURNAL; SIGNAL TRANSDUCTION;

EID: 79953306252     PISSN: 13816128     EISSN: None     Source Type: Journal    
DOI: 10.2174/138161211795164176     Document Type: Article

References (228)

1. Furchgott RF, Zawadzki JV. The obligatory role of endothelial cells in the relaxation of arterial smooth muscle by acetylcholine. Nature 1980; 288(5789): 373-6.
2. Hobbs, AJ, Higgs, A Moncada S Inhibition of nitric oxide synthase as a potential therapeutic target Annual Review of Pharmacology and Toxicology 1999 39: 191-220
3. Guix FX, Uribesalgo I, Coma M, Muñoz FJ. The physiology and pathophysiology of nitric oxide in the brain. Prog Neurobiol 2005; 76(2): 126-52.
4. Calabrese V, Cornelius C, Rizzarelli E, Owen JB, Dinkova-Kostova AT, Butterfield DA. Nitric oxide in cell survival: a janus molecule. Antioxid Redox Signal 2009; 11(11): 2717-39.
5. Wang Q, Cwik M, Wright CJ, Cunningham F, Pelligrino DA. The in vivo unidirectional conversion of nitro-D-arginine to nitro-L- arginine. J Pharmacol Exp Ther 1999; 288(1): 270-3.
6. Mungrue IN, Bredt DS, Stewart, DJ and Husain M. From mole-cules to mammals: what's NOS got to do with it? J Cell Sci 2004; 117(Pt 13): 2627-9. Acta Physiologica Scandinavica 2003 179: 123-135
7. Steinert JR, Chernova T, Forsythe ID. Nitric oxide signaling in brain function, dysfunction, and dementia. Neuroscientist 2010; 16(4): 435-52.
8. Hopper R, Lancaster B, Garthwaite J. On the regulation of NMDA receptors by nitric oxide. Eur J Neurosci 2004; 19(7): 1675-82.
9. Lugnier C. Cyclic nucleotide phosphodiesterase (PDE) superfa-mily: a new target for the development of specific therapeutic agents. Pharmacol Ther 2006; 109(3): 366-98.
10. Menniti FS, Chappie TA, Humphrey JM, Schmidt CJ. Phosphodi-esterase 10A inhibitors: a novel approach to the treatment of the symptoms of schizophrenia. Curr Opin Investig Drugs 2007; 8(1): 54-9.
11. Esplugues JV. NO as a signalling molecule in the nervous system. Br J Pharmacol 2002; 135(5): 1079-95.
12. Stamler JS, Toone EJ, Lipton SA, Sucher NJ. (S)NO signals: trans-location, regulation, and a consensus motif. Neuron 1997; 18(5): 691-6.
13. Tsang AH, Chung KK. Oxidative and nitrosative stress in Parkin-son's disease. Biochim Biophys Acta 2009; 1792(7): 643-50.
14. Contestabile A. Roles of NMDA receptor activity and nitric oxide production in brain development. Brain Res Rev 2000; 32(2-3): 476-509.
15. Bredt DS. Endogenous nitric oxide synthesis: biological functions and pathophysiology. Free Radic Res 1999; 31(6): 577-96.
16. Beckman JS, Ischiropoulos H, Zhu L, van der Woerd M, Smith C, Chen J, Harrison J, Martin JC, Tsai M. Kinetics of superoxide dis- mutase- and iron-catalyzed nitration of phenolics by peroxynitrite. Arch Biochem Biophys 1992; 298(2): 438-45.
17. Ischiropoulos H, Zhu L, Chen J, Tsai M, Martin JC, Smith CD, Beckman JS. Peroxynitrite-mediated tyrosine nitration catalyzed by superoxide dismutase. Arch Biochem Biophys 1992; 298(2): 431-7.
18. Yokoyama H, Kuroiwa H, Yano R, Araki T. Targeting reactive oxygen species, reactive nitrogen species and inflammation in MPTP neurotoxicity and Parkinson's disease. Neurol Sci 2008; 29(5): 293-301.
19. Calabrese V, Mancuso C, Calvani M, Rizzarelli E, Butterfield DA, Stella AM. Nitric oxide in the central nervous system: neuroprotec- tion versus neurotoxicity. Nat Rev Neurosci 2007; 8(10): 766-75.
20. Contestabile A. Regulation of transcription factors by nitric oxide in neurons and in neural-derived tumor cells. Prog Neurobiol 2008; 84(4): 317-28.
21. Moncada S, Bolaños JP. Nitric oxide, cell bioenergetics and neu-rodegeneration. J Neurochem 2006; 97(6): 1676-89.
22. Garthwaite J. Concepts of neural nitric oxide-mediated transmis-sion. Eur J Neurosci 2008; 27(11): 2783-802.
23. Mustafa AK, Gadalla MM, Snyder SH. Signaling by gasotransmit-ters. Sci Signal 2009; 2(68).
24. Del Bel EA, Guimarães FS, Bermúdez-Echeverry M, et al. Role of nitric oxide on motor behavior. Cell Mol Neurobiol 2005; 25(2): 371-92.
25. Araki T, Mizutani H, Matsubara M, Imai Y, Mizugaki M, Itoyama Y. Nitric oxide synthase inhibitors cause motor deficits in mice. Eur Neuropsychopharmacol 2001; 11(2): 125-33.
26. Dall'Igna OP, Dietrich MO, Hoffmann A, et al. Catalepsy and hypolocomotion induced by a nitric oxide donor: attenuation by theophylline. Eur J Pharmacol 2001; 432(1): 29-33.
27. Del Bel EA, Souza AS, Guimarães FS, da-Silva CA, Nucci-da-Silva LP. Motor effects of acute and chronic inhibition of nitric ox- ide synthesis in mice. Psychopharmacology (Berl) 2002; 161(1): 32-7.
28. Dzoljic E, De Vries R, Dzoljic MR. New and potent inhibitors of nitric oxide synthase reduce motor activity in mice. Behav Brain Res 1997; 87(2): 209-12.
29. Starr MS, Starr BS. Do NMDA receptor-mediated changes in mo-tor behaviour involve nitric oxide? Eur J Pharmacol 1995; 272(2-3): 211-7.
30. Uzbay IT. L-NAME precipitates catatonia during ethanol with-drawal in rats. Behav Brain Res 2001; 119(1): 71-6.
31. Huang PL, Dawson TM, Bredt DS, Snyder SH, Fishman MC. Targeted disruption of the neuronal nitric oxide synthase gene. Cell 1993; 75(7): 1273-86.
32. Nelson RJ, Demas GE, Huang PL, et al. Behavioural abnormalities in male mice lacking neuronal nitric oxide synthase. Nature 1995; 378(6555): 383-6.
33. Weitzdoerfer R, Hoeger H, Engidawork E, et al. Neuronal nitric oxide synthase knock-out mice show impaired cognitive perform-ance. Nitric Oxide 2004; 10(3): 130-40.
34. Eliasson MJ, Blackshaw S, Schell MJ, Snyder SH. Neuronal nitric oxide synthase alternatively spliced forms: prominent functional localizations in the brain. Proc Natl Acad Sci USA 1997; 94(7): 3396-401.
35. Gyurko R, Leupen S, Huang PL. Deletion of exon 6 of the neuronal nitric oxide synthase gene in mice results in hypogonadism and in- fertility. Endocrinology 2002; 143(7): 2767-74
36. Langnaese K, Richter K, Smalla KH, et al. Splice-isoform specific immunolocalization of neuronal nitric oxide synthase in mouse and rat brain reveals that the PDZ-complex-building nNOSalpha beta-finger is largely exposed to antibodies. Dev Neurobiol 2007; 67(4): 422-37.
37. Bilbo SD, Hotchkiss AK, Chiavegatto S, Nelson RJ. Blunted stress responses in delayed type hypersensitivity in mice lacking the neu- ronal isoform of nitric oxide synthase. J Neuroimmunol 2003; 140(1-2): 41-8.
38. Tanda K, Nishi A, Matsuo N, et al. Abnormal social behavior, hyperactivity, impaired remote spatial memory, and increased D1- mediated dopaminergic signaling in neuronal nitric oxide synthase knockout mice. Mol Brain 2009; 2(1): 19.
39. Maren S. Effects of 7-nitroindazole, a neuronal nitric oxide syn-thase (nNOS) inhibitor, on locomotor activity and contextual fear conditioning in rats. Brain Res 1998; 804(1): 155-8.
40. Volke V, Wegener G, Vasar E. Augmentation of the NO-cGMP cascade induces anxiogenic-like effect in mice. J Physiol Pharma- col 2003; 54(4): 653-60.
41. Stewart TL, Michel AD, Black MD, Humphrey PP. Evidence that nitric oxide causes calcium-independent release of [3H] dopa-mine from rat striatum in vitro. J Neurochem 1996; 66(1): 131-7.
42. Abekawa T, Ohmori T, Koyama T. Effect of NO synthase inhibi-tion on behavioral changes induced by a single administration of methamphetamine. Brain Res 1994; 666(1): 147-50.
43. Kriegsfeld LJ, Eliasson MJ, Demas GE, et al. Nocturnal motor coordination deficits in neuronal nitric oxide synthase knock-out mice. Neuroscience 1999; 89(2): 311-5.
44. Chiavegatto S, Dawson VL, Mamounas LA, Koliatsos VE, Dawson TM, Nelson RJ. Brain serotonin dysfunction accounts for aggres- sion in male mice lacking neuronal nitric oxide synthase. Proc Natl Acad Sci USA 2001; 98(3): 1277-81.
45. Goldberger ME, Bregman BS, Vierck CJ, Brown M. Criteria for assessing recovery of function after spinal cord injury: behavioral methods. Exp Neurol 1990; 107(2): 113-7.
46. Noda Y, Yamada K, Furukawa H, Nabeshima T. Involvement of nitric oxide in phencyclidine-induced hyperlocomotion in mice. Eur J Pharmacol 1995; 286(3): 291-7.
47. Lino de Oliveira C, Guimarães FS, Del Bel EA. C-jun mRNA ex-pression in the hippocampal formation induced by restraint stress. Brain Res 1997; 753(2): 202-8.
48. Marras RA, Martins AP, Del Bel EA, Guimarães FS. L-NOARG, an inhibitor of nitric oxide synthase, induces catalepsy in mice. Neuroreport 1995; 7(1): 158-60.
49. Del Bel EA, Guimarães FS. Sub-chronic inhibition of nitric-oxide synthesis modifies haloperidol-induced catalepsy and the number of NADPH-diaphorase neurons in mice. Psychopharmacology (Berl) 2000; 147(4): 356-61.
50. Del Bel EA, Silveira MC, Graeff FG, Garcia-Cairasco N, Gui-marães FS. Differential expression of c-fos mRNA and Fos protein in the rat brain after restraint stress or pentylenetetrazol-induced seizures. Cell Mol Neurobiol 1998; 18(3): 339-46.
51. Cavas M, Navarro JF. Coadministration of L-NOARG and tiapride: effects on catalepsy in male mice. Prog Neuropsychopharmacol Biol Psychiatry 2002; 26(1): 69-73.
52. Lazzarini M, Salum C, Del Bel EA. Combined treatment of ascor-bic acid or alpha-tocopherol with dopamine receptor antagonist or nitric oxide synthase inhibitor potentiates cataleptic effect in mice. Psychopharmacology (Berl) 2005; 181(1): 71-9.
53. Del-Bel EA, Guimarães FS, Joca SR, Echeverry MB, Ferreira FR. Tolerance to the cataleptic effect that follows repeated nitric oxide synthase inhibition may be related to functional enzymatic recov-ery. J Psychopharmacol 2010; 24(3): 397-405.
54. Del Bel EA, da Silva CA, Guimarães FS, Bermúdez-Echeverry M. Catalepsy induced by intra-striatal administration of nitric oxide synthase inhibitors in rats. Eur J Pharmacol 2004; 485(1-3): 175-81.
55. Echeverry MB, Guimarães FS, Del Bel EA. Acute and delayed restraint stress-induced changes in nitric oxide producing neurons in limbic regions. Neuroscience 2004; 125(4): 981-93.
56. Sugaya K, McKinney M. Nitric oxide synthase gene expression in cholinergic neurons in the rat brain examined by combined immu- nocytochemistry and in situ hybridization histochemistry. Brain Res Mol Brain Res 1994; 23(1-2): 111-25.
57. Agid Y, Ruberg M, Dubois B, et al. Parkinson's disease and de-mentia. Clin Neuropharmaco 1986; 9 Suppl 2: S22-36.
58. Fahn S. Concept and classification of dystonia. Adv Neurol 1988; 50: 1-8.
59. Koob GF, Simon H, Herman JP, Le Moal M. Neuroleptic-like disruption of the conditioned avoidance response requires destruc- tion of both the mesolimbic and nigrostriatal dopamine systems. Brain Res 1984; 303(2): 319-29.
60. Osborne PG, O'Connor WT, Beck O, Ungerstedt U. Acute versus chronic haloperidol: relationship between tolerance to catalepsy and striatal and accumbens dopamine, GABA and acetylcholine re-lease. Brain Res 1994; 634(1): 20-30.
61. Koffer KB, Berney S, Hornykiewicz O. The role of the corpus striatum in neuroleptic- and narcotic-induced catalepsy. Eur J Pharmacol 1978; 47(1): 81-6.
62. Sanberg PR, Bunsey MD, Giordano M, Norman AB. The catalepsy test: its ups and downs. Behav Neurosci 1988; 102(5): 748-59.
63. Przedborski S, Jackson-Lewis V, Yokoyama R, Shibata T, Dawson VL, Dawson TM. Role of neuronal nitric oxide in 1-methyl-4- phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced dopaminergic neurotoxicity. Proc Natl Acad Sci USA 1996; 93(10): 4565-71.
64. Dehmer T, Lindenau J, Haid S, Dichgans J, Schulz JB. Deficiency of inducible nitric oxide synthase protects against MPTP toxicity in vivo. J Neurochem 2000; 74(5): 2213-6.
65. Zhang J, Graham DG, Montine TJ, Ho YS. Enhanced N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine toxicity in mice deficient in CuZn-superoxide dismutase or glutathione peroxidase. J Neuropa-thol Exp Neurol 2000; 59(1): 53-61.
66. Duncan AJ, Heales SJ. Nitric oxide and neurological disorders. Mol Aspects Med 2005; 26(1-2): 67-96.
67. Zhang L, Li L, Prabhakaran K, Borowitz JL, Isom GE. Trimeth-yltin-induced apoptosis is associated with upregulation of inducible nitric oxide synthase and Bax in a hippocampal cell line. Toxicol Appl Pharmacol 2006; 216(1): 34-43.
68. Richter A, Löschmann PA, Löscher W. Antidystonic efficacy of nitric oxide synthase inhibitors in a rodent model of primary parox- ysmal dystonia. Br J Pharmacol 2000; 131(5): 921-6.
69. Kuiper MA, Visser JJ, Bergmans PL, Scheltens P, Wolters EC. Decreased cerebrospinal fluid nitrate levels in Parkinson's disease, Alzheimer's disease and multiple system atrophy patients. J Neurol Sci 1994; 121(1): 46-9.
70. Foxton RH, Land JM, Heales SJ. Tetrahydrobiopterin availability in Parkinson's and Alzheimer's disease; potential pathogenic mechanisms. Neurochem Res 2007; 32(4-5): 751-6.
71. Gatto EM, Riobó NA, Carreras MC, et al. Overexpression of neu-trophil neuronal nitric oxide synthase in Parkinson's disease. Nitric Oxide 2000; 4(5): 534-9.
72. Levecque C, Elbaz A, Clavel J, et al. Association between Parkinson's disease and polymorphisms in the nNOS and iNOS genes in a community-based case-control study. Hum Mol Genet 2003; 12(1): 79-86.
73. Salum C, Raisman-Vozari R, Michel PP, et al. Modulation of do-pamine uptake by nitric oxide in cultured mesencephalic neurons. Brain Res 2008; 1198: 27-33.
74. Egberongbe YI, Gentleman SM, Falkai P, Bogerts B, Polak JM, Roberts GW. The distribution of nitric oxide synthase immunoreac- tivity in the human brain. Neuroscience 1994; 59(3): 561-78.
75. Jenner P. Molecular mechanisms of L-DOPA-induced dyskinesia. Nat Rev Neurosci 2008; 9(9): 665-77.
76. Deumens R, Blokland A, Prickaerts J. Modeling Parkinson's dis-ease in rats: an evaluation of 6-OHDA lesions of the nigrostriatal pathway. Exp Neurol 2002; 175(2): 303-17.
77. Saner A, Thoenen H. Model experiments on the molecular mecha-nism of action of 6-hydroxydopamine. Mol Pharmacol 1971; 7(2): 147-54.
78. Ungerstedt U. 6-Hydroxy-dopamine induced degeneration of cen-tral monoamine neurons. Eur J Pharmacol 1968; 5(1): 107-10.
79. Ungerstedt U. Postsynaptic supersensitivity after 6-hydroxy-dopamine induced degeneration of the nigro-striatal dopamine sys-tem. Acta Physiol Scand Suppl 1971; 367: 69-93.
80. Ungerstedt U. Striatal dopamine release after amphetamine or nerve degeneration revealed by rotational behaviour. Acta Physiol Scand Suppl 1971; 367: 49-68.
81. Burns RS, Chiueh CC, Markey SP, Ebert MH, Jacobowitz DM, Kopin IJ. A primate model of parkinsonism: selective destruction of dopaminergic neurons in the pars compacta of the substantia ni-gra by N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Proc Natl Acad Sci USA 1983; 80(14): 4546-50.
82. Kühn K, Wellen J, Link N, Maskri L, Lübbert H, Stichel CC. The mouse MPTP model: gene expression changes in dopaminergic neurons. Eur J Neurosci 2003; 17(1): 1-12.
83. Mufson EJ, Brandabur MM. Sparing of NADPH-diaphorase striatal neurons in Parkinson's and Alzheimer's diseases. Neuroreport 1994; 5(6): 705-8.
84. Eve DJ, Nisbet AP, Kingsbury AE, et al. Basal ganglia neuronal nitric oxide synthase mRNA expression in Parkinson's disease. Brain Res Mol Brain Res 1998; 63(1): 62-71.
85. Hunot S, Boissière F, Faucheux B, et al. Nitric oxide synthase and neuronal vulnerability in Parkinson's disease. Neuroscience 1996; 72(2): 355-63.
86. Gomes MZ, Del Bel EA. Effects of electrolytic and 6- hydroxydopamine lesions of rat nigrostriatal pathway on nitric ox-ide synthase and nicotinamide adenine dinucleotide phosphate diaphorase. Brain Res Bull 2003; 62(2): 107-15.
87. Gomes MZ, Raisman-Vozari R, Del Bel EA. A nitric oxide syn-thase inhibitor decreases 6-hydroxydopamine effects on tyrosine hydroxylase and neuronal nitric oxide synthase in the rat nigrostri-atal pathway. Brain Res 2008; 1203: 160-9.
88. Ponzoni S, Guimarães FS, Del Bel EA, Garcia-Cairasco N. Behav-ioral effects of intra-nigral microinjections of manganese chloride: interaction with nitric oxide. Prog Neuropsychopharmacol Biol Psychiatry 2000; 24(2): 307-25.
89. Sancesario G, Giorgi M, D'Angelo V, Modica A, Martorana A, Morello M,. Down-regulation of nitrergic transmission in the rat striatum after chronic nigrostriatal deafferentation. Eur J Neurosci 2004; 20(4): 989-1000.
90. Liberatore GT, Jackson-Lewis V, Vukosavic S, et al, Inducible nitric oxide synthase stimulates dopaminergic neurodegeneration in the MPTP model of Parkinson's disease 1999; Nat. Med. 5: 1403-1409.
91. Muramatsu Y, Kurosaki R, Watanabe H, et al. Cerebral alterations in a MPTP-mouse model of Parkinson's disease-an immunocyto- chemical study. J Neural Transm 2003; 110(10): 1129-44.
92. Barthwal MK, Srivastava N, Nag D, Seth PK, Srimal RC, Dikshit M. Antioxidant levels in the rat brain after nitric oxide synthase in- hibition: a preliminary report. Redox Rep 2000; 5(2-3): 75-80.
93. de Vente J, Markerink-van Ittersum M, van Abeelen J, Emson PC, Axer H, Steinbusch HW. NO-mediated cGMP synthesis in cho- linergic neurons in the rat forebrain: effects of lesioning dopa-minergic or serotonergic pathways on nNOS and cGMP synthesis. Eur J Neurosci 2000; 12(2): 507-19.
94. Sahach VF, Baziliuk OV, Oleshko MM, Kotsiuruba OV, Buk-hanevych OM, Appenzeller O. [The nitric oxide system in a chronic deficiency of mesostriatal dopamine: the action of nitro-glycerin]. Fiziol Zh 2000; 46(2): 55-63.
95. Matthews RT, Beal MF, Fallon J, et al. MPP+ induced substantia nigra degeneration is attenuated in nNOS knockout mice. Neuro- biol Dis 1997; 4(2): 114-21.
96. Schulz JB, Matthews RT, Muqit MM, Browne SE, Beal MF. Inhi-bition of neuronal nitric oxide synthase by 7-nitroindazole protects against MPTP-induced neurotoxicity in mice. J Neurochem 1995; 64(2): 936-9.
97. Hantraye P, Brouillet E, Ferrante R, et al. Inhibition of neuronal nitric oxide synthase prevents MPTP-induced parkinsonism in ba- boons. Nat Med 1996; 2(9): 1017-21.
98. Di Matteo V, Benigno A, Pierucci M, et al. 7-nitroindazole protects striatal dopaminergic neurons against MPP+-induced degeneration: an in vivo microdialysis study. Ann N Y Acad Sci 2006; 1089: 462-71.
99. Kurosaki R, Muramatsu Y, Michimata M, et al. Role of nitric oxide synthase against MPTP neurotoxicity in mice. Neurol Res 2002; 24(7): 655-62.
100. Watanabe Y, Kato H, Araki T. Protective action of neuronal nitric oxide synthase inhibitor in the MPTP mouse model of arkinson's disease. Metab Brain Dis 2008; 23(1): 51-69.
101. Chalimoniuk M, Langfort J, Lukacova N, Marsala J. Upregulation of guanylyl cyclase expression and activity in striatum of MPTP- induced parkinsonism in mice. Biochem Biophys Res Commun 2004; 324(1): 118-26.
102. Chalimoniuk M, Stepie A, Strosznajder JB. Pergolide mesylate, a dopaminergic receptor agonist, applied with L-DOPA enhances se- rum antioxidant enzyme activity in Parkinson disease. Clin Neuro-pharmacol 2004; 27(5): 223-9.
103. Chalimoniuk M, Lukacova N, Marsala J, Langfort J. Alterations of the expression and activity of midbrain nitric oxide synthase and solubleguanylylcyclasein1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine-induced Parkinsonism in mice. Neuroscience 2006; 141(2): 1033-46.
104. He Y, Imam SZ, Dong Z, et al. Role of nitric oxide in rotenone-induced nigro-striatal injury. J Neurochem 2003; 86(6): 1338-45.
105. Iravani MM, Kashefi K, Mander P, Rose S, Jenner P. Involvement of inducible nitric oxide synthase in inflammation-induced dopa- minergic neurodegeneration. Neuroscience 2002; 110(1): 49-58.
106. Possel H, Noack H, Putzke J, Wolf G, Sies H. Selective upregula-tion of inducible nitric oxide synthase (iNOS) by lipopolysaccha- ride (LPS) and cytokines in microglia: in vitro and in vivo studies. Glia 2000; 32(1): 51-9.
107. Castaño A, Herrera AJ, Cano J, Machado A. Lipopolysaccharide intranigral injection induces inflammatory reaction and damage in nigrostriatal dopaminergic system. J Neurochem 1998; 70(4): 1584-92.
108. Barthwal MK, Srivastava N, Dikshit M. Role of nitric oxide in a progressive neurodegeneration model of Parkinson's disease in the rat. Redox Rep 2001; 6(5): 297-302.
109. Arimoto T, Bing G. Up-regulation of inducible nitric oxide syn-thase in the substantia nigra by lipopolysaccharide causes micro- glial activation and neurodegeneration. Neurobiol Dis 2003; 12(1): 35-45.
110. Singh S, Das T, Ravindran A, et al. Involvement of nitric oxide in neurodegeneration: a study on the experimental models of Parkin- son's disease. Redox Rep 2005; 10(2): 103-9.
111. Salerno L, Sorrenti V, Di Giacomo C, Romeo G, Siracusa MA Progress in the development of selective nitric oxide synthase (NOS) inhibitors 2002 Curr Pharm Des.; 8(3): 177-200.
112. Obeso JA, Olanow CW, Nutt JG. Levodopa motor complications in Parkinson's disease. Trends Neurosci 2000; 23(10 Suppl): S2-7
113. Cenci MA, Lindgren HS. Advances in understanding L-DOPA-induced dyskinesia. Curr Opin Neurobiol 2007; 17(6): 665-71.
114. Santini E, Valjent E, Fisone G. Parkinson's disease: levodopa-induced dyskinesia and signal transduction. FEBS J 2008; 275(7): 1392-9.
115. Nutt D. Not only but also? Comments on How does convulsive therapy work? Neuropsychopharmacology 1990; 3(2): 93-5; dis- cussion 7-9.
116. Olanow CW, Agid Y, Mizuno Y, et al. Levodopa in the treatment of Parkinson's disease: current controversies. Mov Disord 2004; 19(9): 997-1005.
117. Fahn S, Group atPS. Does levodopa slow or hasten the rate of progression of Parkinson's disease? J Neurol 2005; 252 Suppl 4: IV37-IV42.
118. Cenci MA, Lundblad M. Ratings of L-DOPA-induced dyskinesia in the unilateral 6-OHDA lesion model of Parkinson's disease in rats and mice. Curr Protoc Neurosci 2007; Chapter 9: Unit 9.25.
119. Papa SM, Engber TM, Kask AM, Chase TN. Motor fluctuations in levodopa treated parkinsonian rats: relation to lesion extent and treatment duration. Brain Res 1994; 662(1-2): 69-74.
120. Henry B, Crossman AR, Brotchie JM. Characterization of en-hanced behavioral responses to L-DOPA following repeated ad- ministration in the 6-hydroxydopamine-lesioned rat model of Park-inson's disease. Exp Neurol 1998; 151(2): 334-42.
121. Mura A, Mintz M, Feldon J. Behavioral and anatomical effects of long-term L-dihydroxyphenylalanine (L-DOPA) administration in rats with unilateral lesions of the nigrostriatal system. Exp Neurol 2002; 177(1): 252-64.
122. Cenci MA, Lee CS, Björklund A. L-DOPA-induced dyskinesia in the rat is associated with striatal overexpression of prodynorphin- and glutamic acid decarboxylase mRNA. Eur J Neurosci 1998; 10(8): 2694-706.
123. Lundblad M, Usiello A, Carta M, Håkansson K, Fisone G, Cenci MA. Pharmacological validation of a mouse model of l-DOPA- induced dyskinesia. Exp Neurol 2005; 194(1): 66-75.
124. Pavón N, Martín AB, Mendialdua A, Moratalla R. ERK phos-phorylation and FosB expression are associated with L-DOPA- induced dyskinesia in hemiparkinsonian mice. Biol Psychiatry 2006; 59(1): 64-74.
125. Monville C, Torres EM, Dunnett SB. Validation of the l-dopa- induced dyskinesia in the 6-OHDA model and evaluation of the ef-fects of selective dopamine receptor agonists and antagonists. Brain Res Bull 2005; 68(1-2): 16-23.
126. Lane E, Dunnett S. Animal models of Parkinson's disease and L-dopa induced dyskinesia: how close are we to the clinic? Psycho- pharmacology (Berl) 2008; 199(3): 303-12.
127. Andringa G, Vermeulen RJ, Drukarch B, Renier WO, Stoof JC, Cools AR. The validity of the pretreated, unilaterally MPTP-treated monkeys as a model of Parkinson's disease: a detailed behavioural analysis of the therapeutic and undesired effects of the D2 agonist quinpirole and the D1 agonist SKF 81297. Behav Pharmacol 1999; 10(2): 163-73.
128. Gumulka SW, Dinnendahl V, Schönhöfer PS, Stock K. Dopa-minergic timulants and cyclic nucleotides in mouse brain. Effects of dopaminergic antagonists, olinolytics, and GABA agonists. Naunyn Schmiedebergs Arch Pharmacol 1976; 295(1): 21-6.
129. Sanchez JJ, Abreu P, Gonzalez MC. Sodium nitroprusside stimu-lates L-DOPA release from striatal tissue through nitric oxide and cGMP. Eur J Pharmacol 2002; 438(1-2): 79-83.
130. Itokawa K, Ohkuma A, Araki N, Tamura N, Shimazu K. Effect of L-DOPA on nitric oxide production in striatum of freely mobile mice. Neurosci Lett 2006; 402(1-2): 142-4.
131. Chalimoniuk M, Langfort J. The effect of subchronic, intermittent L-DOPA treatment on neuronal nitric oxide synthase and soluble guanylyl cyclase expression and activity in the striatum and mid- brain of normal and MPTP-treated mice. Neurochem Int 2007; 50(6): 821-33.
132. Padovan-Neto FE, Echeverry MB, Tumas V, Del-Bel EA. Nitric oxide synthase inhibition attenuates L-DOPA-induced dyskinesias in a rodent model of Parkinson's disease. Neuroscience 2009; 159(3): 927-35.
133. Novaretti N, Padovan-Neto FE, Tumas V, da-Silva CA, Del Bel EA. Lack of tolerance for the anti-dyskinetic effects of 7- nitroindazole, a neuronal nitric oxide synthase inhibitor, in rats. Braz J Med Biol Res 2010; 43(11): 1047-53.
134. Whishaw IQ, Hines DJ, Wallace DG. Dead reckoning (path inte-gration) requires the hippocampal formation: evidence from spon- taneous exploration and spatial learning tasks in light (allothetic) and dark (idiothetic) tests. Behav Brain Res 2001; 127(1-2): 49-69.
135. Bradley CA, Padovan JC, Thompson TL, Benoit CA, Chait BT, Rhoads RE. Mass spectrometric analysis of the N terminus of translational initiation factor eIF4G-1 reveals novel isoforms. J Biol Chem 2002; 277(15): 12559-71.
136. Gainetdinov RR, Mohn AR, Bohn LM, Caron MG. Glutamatergic modulation of hyperactivity in mice lacking the dopamine trans- porter. Proc Natl Acad Sci USA 2001; 98(20): 11047-54.
137. Tarantino LM, Bucan M. Dissection of behavior and psychiatric disorders using the mouse as a model. Hum Mol Genet 2000; 9(6): 953-65.
138. Lundblad M, Picconi B, Lindgren H, Cenci MA. A model of L-DOPA-induced dyskinesia in 6-hydroxydopamine lesioned mice: relation to motor and cellular parameters of nigrostriatal function. Neurobiol Dis 2004; 16(1): 110-23.
139. Lees A. Alternatives to levodopa in the initial treatment of early Parkinson's disease. Drugs Aging 2005; 22(9): 731-40.
140. Hallett PJ, Standaert DG. Rationale for and use of NMDA receptor antagonists in Parkinson's disease. Pharmacol Ther 2004; 102(2): 155-74.
141. Rezak M. Current pharmacotherapeutic treatment options in Park- inson's disease. Dis Mon 2007; 53(4): 214-22.
142. Stoof JC, Booij J, Drukarch B, Wolters EC. The anti-parkinsonian drug amantadine inhibits the N-methyl-D-aspartic acid-evoked re- lease of acetylcholine from rat neostriatum in a non-competitive way. Eur J Pharmacol 1992; 213(3): 439-43.
143. Dwyer MA, Bredt DS, Snyder SH. Nitric oxide synthase: irreversi-ble inhibition by L-NG-nitroarginine in brain in vitro and in vivo. Biochem Biophys Res Commun 1991; 176(3): 1136-41.
144. Carreau A, Duval D, Poignet H, Scatton B, Vigé X, Nowicki JP. Neuroprotective efficacy of N omega-nitro-L-arginine after focal cerebral ischemia in the mouse and inhibition of cortical nitric ox-ide synthase. Eur J Pharmacol 1994; 256(3): 241-9.
145. Traystman RJ, Moore LE, Helfaer MA, et al. Nitro-L-arginine analogues. Dose- and time-related nitric oxide synthase inhibition in brain. Stroke 1995; 26(5): 864-9.
146. Sammut S, Dec A, Mitchell D, Linardakis J, Ortiguela M, West AR. Phasic dopaminergic transmission increases NO efflux in the rat dorsal striatum via a neuronal NOS and a dopamine D(1/5) re-ceptor-dependent mechanism. Neuropsychopharmacology 2006; 31(3): 493-505.
147. St-Pierre JA, Bédard PJ. Systemic administration of the NMDA receptor antagonist MK-801 potentiates circling induced by in- trastriatal microinjection of dopamine. Eur J Pharmacol 1995; 272(2-3): 123-9.
148. Cenci MA, Tranberg A, Andersson M, Hilbertson A. Changes in the regional and compartmental distribution of FosB- and JunB-like immunoreactivity induced in the dopamine-denervated rat striatum by acute or chronic L-dopa treatment. Neuroscience 1999; 94(2): 515-27.
149. Tekumalla PK, Calon F, Rahman Z, et al. Elevated levels of Delta-FosB and RGS9 in striatum in Parkinson's disease. Biol Psychiatry 2001; 50(10): 813-6.
150. Hiroi N, Brown JR, Haile CN, Ye H, Greenberg ME, Nestler EJ. FosB mutant mice: loss of chronic cocaine induction of Fos-related proteins and heightened sensitivity to cocaine's psychomotor and rewarding effects. Proc Natl Acad Sci USA 1997; 94(19): 10397-402.
151. Hiroi N, Marek GJ, Brown JR, et al. Essential role of the fosB gene in molecular, cellular, and behavioral actions of chronic electro- convulsive seizures. J Neurosci 1998; 18(17): 6952-62.
152. Kelz MB, Chen J, Carlezon WA, et al. Expression of the transcrip-tion factor deltaFosB in the brain controls sensitivity to cocaine. Nature 1999; 401(6750): 272-6.
153. Darmopil S, Martín AB, De Diego IR, Ares S, Moratalla R. Ge-netic inactivation of dopamine D1 but not D2 receptors inhibits L- DOPA-induced dyskinesia and histone activation. Biol Psychiatry 2009; 66(6): 603-13.
154. Santini E, Alcacer C, Cacciatore S, et al. L-DOPA activates ERK signaling and phosphorylates histone H3 in the striatonigral me- dium spiny neurons of hemiparkinsonian mice. J Neurochem 2009; 108(3): 621-33.
155. Brotchie JM, Lee J, Venderova K. Levodopa-induced dyskinesia in Parkinson's disease. J Neural Transm 2005; 112(3): 359-91.
156. Centonze D, Gubellini P, Bernardi G, Calabresi P. Permissive role of interneurons in corticostriatal synaptic plasticity. Brain Res Brain Res Rev 1999; 31(1): 1-5.
157. Morello M, Reiner A, Sancesario G, Karle EJ, Bernardi G. Ultra-structural study of nitric oxide synthase-containing striatal neurons and their relationship with parvalbumin-containing neurons in rats. Brain Res 1997; 776(1-2): 30-9.
158. Sancesario G, Morello M, Reiner A, et al. Nitrergic neurons make synapses on dual-input dendritic spines of neurons in the cerebral cortex and the striatum of the rat: implication for a postsynaptic ac-tion of nitric oxide. Neuroscience 2000; 99(4): 627-42.
159. Fujiyama F, Masuko S. Association of dopaminergic terminals and neurons releasing nitric oxide in the rat striatum: an electron micro- scopic study using NADPH-diaphorase histochemistry and tyrosine hydroxylase immunohistochemistry. Brain Res Bull 1996; 40(2): 121-7.
160. Benavides-Piccione R, DeFelipe J. Different populations of tyro-sine-hydroxylase-immunoreactive neurons defined by differential expression of nitric oxide synthase in the human temporal cortex. Cereb Cortex 2003; 13(3): 297-307.
161. Kawaguchi Y. Physiological, morphological, and histochemical characterization of three classes of interneurons in rat neostriatum. J Neurosci 1993; 13(11): 4908-23.
162. Kawaguchi Y, Wilson CJ, Augood SJ, Emson PC. Striatal interneu-rones: chemical, physiological and morphological characterization. Trends Neurosci 1995; 18(12): 527-35.
163. Kubota Y, Kawaguchi Y. Spatial distributions of chemically identi-fied intrinsic neurons in relation to patch and matrix compartments of rat neostriatum. J Comp Neurol 1993; 332(4): 499-513.
164. Moratalla R, Vallejo M, Elibol B, Graybiel AM. D1-class dopa-mine receptors influence cocaine-induced persistent expression of Fos-related proteins in striatum. Neuroreport 1996; 8(1): 1-5.
165. Cao X, Yasuda T, Uthayathas S, et al et al. Striatal overexpression of DeltaFosB reproduces chronic levodopa-induced involuntary movements. J Neurosci 2010; 30(21): 7335-43.
166. Cenci MA, Björklund A. Transection of corticostriatal afferents reduces amphetamine- and apomorphine-induced striatal Fos ex- pression and turning behaviour in unilaterally 6-hydroxydopamine-lesioned rats. Eur J Neurosci 1993; 5(8): 1062-70.
167. Konradi C, Leveque JC, Hyman SE. Amphetamine and dopamine-induced immediate early gene expression in striatal neurons de- pends on postsynaptic NMDA receptors and calcium. J Neurosci 1996; 16(13): 4231-9.
168. Schwarzschild MA, Cole RL, Hyman SE. Glutamate, but not do-pamine, stimulates stress-activated protein kinase and AP-1- mediated transcription in striatal neurons. J Neurosci 1997; 17(10): 3455-66.
169. Jog M, Panisset M, Suchowersky O, Réhel B, Schecter R. Natural-istic evaluation of entacapone in patients with signs and symptoms of L-dopa wearing-off. Curr Med Res Opin 2008; 24(11): 3207-15
170. Donoghue JP, Herkenham M. Neostriatal projections from individ-ual cortical fields conform to histochemically distinct striatal com- partments in the rat. Brain Res 1986; 365(2): 397-403.
171. Kincaid AE, Wilson CJ. Corticostriatal innervation of the patch and matrix in the rat neostriatum. J Comp Neurol 1996; 374(4): 578-92.
172. Das S, Grunert M, Williams L, Vincent SR. NMDA and D1 recep-tors regulate the phosphorylation of CREB and the induction of c- fos in striatal neurons in primary culture. Synapse 1997; 25(3): 227-33.
173. Drinnan SL, Hope BT, Snutch TP, Vincent SR. G(olf) in the basal ganglia. Mol Cell Neurosci 1991; 2(1): 66-70.
174. Bender AT, Beavo JA. PDE1B2 regulates cGMP and a subset of the phenotypic characteristics acquired upon macrophage differen- tiation from a monocyte. Proc Natl Acad Sci USA 2006; 103(2): 460-5.
175. Morris BJ, Höllt V, Herz A. Dopaminergic regulation of striatal proenkephalin mRNA and prodynorphin mRNA: contrasting ef- fects of D1 and D2 antagonists. Neuroscience 1988; 25(2): 525-32.
176. Morris BJ, Simpson CS, Mundell S, Maceachern K, Johnston HM, Nolan AM. Dynamic changes in NADPH-diaphorase staining re- flect activity of nitric oxide synthase: evidence for a dopaminergic regulation of striatal nitric oxide release. Neuropharmacology 1997; 36(11-12): 1589-99.
177. Silva MT, Rose S, Hindmarsh JG, et al. Increased striatal dopamine efflux in vivo following inhibition of cerebral nitric oxide synthase by the novel monosodium salt of 7-nitro indazole. Br J Pharmacol 1995; 114(2): 257-8.
178. Black MD, Matthews EK, Humphrey PP. The effects of a photo-sensitive nitric oxide donor on basal and electrically-stimulated do- pamine efflux from the rat striatum in vitro. Neuropharmacology 1994; 33(11): 1357-65.
179. Iravani MM, Millar J, Kruk ZL. Differential release of dopamine by nitric oxide in subregions of rat caudate putamen slices. J Neu- rochem 1998; 71(5): 1969-77.
180. West AR, Galloway MP. Nitric oxide and potassium chloride-facilitated striatal dopamine efflux in vivo: role of calcium- dependent release mechanisms. Neurochem Int 1998; 33(6): 493-501.
181. West AR, Galloway MP, Grace AA. Regulation of striatal dopa-mine neurotransmission by nitric oxide: effector pathways and sig- naling mechanisms. Synapse 2002; 44(4): 227-45.
182. Grasbon-Frodl EM, Brundin P. Mesencephalic neuron death in-duced by congeners of nitrogen monoxide is prevented by the laz- aroid U-83836E. Exp Brain Res 1997; 113(1): 138-43.
183. Trabace L, Kendrick KM. Nitric oxide can differentially modulate striatal neurotransmitter concentrations via soluble guanylate cy- clase and peroxynitrite formation. J Neurochem 2000; 75(4): 1664-74.
184. Grace AA. Physiology of the normal and dopamine-depleted basal ganglia: insights into levodopa pharmacotherapy. Mov Disord 2008; 23 Suppl 3: S560-9.
185. Guevara-Guzman R, Emson PC, Kendrick KM. Modulation of in vivo striatal transmitter release by nitric oxide and cyclic GMP. J Neurochem 1994; 62(2): 807-10.
186. Kiss JP, Vizi ES. Nitric oxide: a novel link between synaptic and nonsynaptic transmission. Trends Neurosci 2001; 24(4): 211-5.
187. Pögün S, Kuhar MJ. Regulation of neurotransmitter reuptake by nitric oxide. Ann N Y Acad Sci 1994; 738: 305-15.
188. Hidaka S, Totterdell S. Ultrastructural features of the nitric oxide synthase-containing interneurons in the nucleus accumbens and their relationship with tyrosine hydroxylase-containing terminals. J Comp Neurol 2001; 431(2): 139-54.
189. West AR, Grace AA. Striatal nitric oxide signaling regulates the neuronal activity of midbrain dopamine neurons in vivo. J Neuro- physiol 2000; 83(4): 1796-808
190. West AR, Grace AA. The nitric oxide-guanylyl cyclase signaling pathway modulates membrane activity States and electrophysi- ological properties of striatal medium spiny neurons recorded in vivo. J Neurosci 2004; 24(8): 1924-35.
191. Sammut S, Bray KE, West AR. Dopamine D2 receptor-dependent modulation of striatal NO synthase activity. Psychopharmacology (Berl) 2007; 191(3): 793-803.
192. Hornykiewicz O. Biochemical aspects of Parkinson's disease. Neu-rology 1998; 51(2 Suppl 2): S2-9.
193. Calon F, Rajput AH, Hornykiewicz O, Bédard PJ, Di Paolo T. Levodopa-induced motor complications are associated with altera- tions of glutamate receptors in Parkinson's disease. Neurobiol Dis 2003; 14(3): 404-16.
194. Gubellini P, Eusebio A, Oueslati A, Melon C, Kerkerian-Le Goff L, Salin P. Chronic high-frequency stimulation of the subthalamic nucleus and L-DOPA treatment in experimental parkinsonism: ef-fects on motor behaviour and striatal glutamate transmission. Eur J Neurosci 2006; 24(6): 1802-14.
195. Calon F, Birdi S, Rajput AH, Hornykiewicz O, Bédard PJ, Di Paolo T. Increase of preproenkephalin mRNA levels in the putamen of Parkinson disease patients with levodopa-induced dyskinesias. J Neuropathol Exp Neurol 2002; 61(2): 186-96.
196. Dunah AW, Wang Y, Yasuda RP, et al. Alterations in subunit expression, composition, and phosphorylation of striatal N-methyl- D-aspartate glutamate receptors in a rat 6-hydroxydopamine model of Parkinson's disease. Mol Pharmacol 2000; 57(2): 342-52.
197. Hallett PJ, Dunah AW, Ravenscroft P, et al. Alterations of striatal NMDA receptor subunits associated with the development of dy- skinesia in the MPTP-lesioned primate model of Parkinson's dis-ease. Neuropharmacology 2005; 48(4): 503-16.
198. Oh JD, Russell DS, Vaughan CL, Chase TN, Russell D. Enhanced tyrosine phosphorylation of striatal NMDA receptor subunits: ef- fect of dopaminergic denervation and L-DOPA administration. Brain Res 1998; 813(1): 150-9.
199. Zeng BY, Iravani MM, Jackson MJ, Rose S, Parent A, Jenner P. Morphological changes in serotoninergic neurites in the striatum and globus pallidus in levodopa primed MPTP treated common marmosets with dyskinesia. Neurobiol Dis 2010; 40(3): 599-607.
200. Rylander D, Iderberg H, Li Q, et al. A mGluR5 antagonist under clinical development improves L-DOPA-induced dyskinesia in parkinsonian rats and monkeys. Neurobiol Dis 2010; 39(3): 352-61.
201. Muñoz A, Li Q, Gardoni F, et al. Combined 5-HT1A and 5-HT1B receptor agonists for the treatment of L-DOPA-induced dyskinesia. Brain 2008; 131(Pt 12): 3380-94.
202. Muñoz A, Carlsson T, Tronci E, Kirik D, Björklund A, Carta M. Serotonin neuron-dependent and -independent reduction of dyski- nesia by 5-HT1A and 5-HT1B receptor agonists in the rat Parkin-son model. Exp Neurol 2009; 219(1): 298-307.
203. Carta M, Carlsson T, Kirik D, Björklund A. Dopamine released from 5-HT terminals is the cause of L-DOPA-induced dyskinesia in parkinsonian rats. Brain 2007; 130(Pt 7): 1819-33.
204. Lopez A, Muñoz A, Guerra MJ, Labandeira-Garcia JL. Mecha-nisms of the effects of exogenous levodopa on the dopamine- denervated striatum. Neuroscience 2001; 103(3): 639-51.
205. Nucci-da-Silva LP, Guimarães FS, Del Bel EA. Serotonin modula-tion of catalepsy induced by N(G)-nitro-L-arginine in mice. Eur J Pharmacol 1999; 379(1): 47-52.
206. Bibbiani F, Oh JD, Kielaite A, Collins MA, Smith C, Chase TN. Combined blockade of AMPA and NMDA glutamate receptors re- duces levodopa-induced motor complications in animal models of PD. Exp Neurol 2005; 196(2): 422-9.
207. Bara-Jimenez W, Bibbiani F, Morris MJ, et al. Effects of serotonin 5-HT1A agonist in advanced Parkinson's disease. Mov Disord 2005; 20(8): 932-6.
208. Olanow CW, Lees A, Obeso J. Levodopa therapy for Parkinson's disease: challenges and future prospects. Mov Disord 2008; 23 Suppl 3: S495-6.
209. Goetz CG, Damier P, Hicking C, et al. Sarizotan as a treatment for dyskinesias in Parkinson's disease: a double-blind placebo- controlled trial. Mov Disord 2007; 22(2): 179-86.
210. Cenci MA, Konradi C. Maladaptive striatal plasticity in L-DOPA-induced dyskinesia. Prog Brain Res 2010; 183: 209-33.
211. Cavalcanti-Kwiatkoski R, Raisman-Vozari R, Ginestet L, Del Bel E. Altered expression of neuronal nitric oxide synthase in weaver mutant mice. Brain Res 2010; 1326: 40-50.
212. Raisman R, Cash R, Agid Y. Parkinson's disease: decreased density of 3H-imipramine and 3H-paroxetine binding sites in putamen. Neurology 1986; 36(4): 556-60.
213. Vallance P. Nitric oxide: therapeutic opportunities. Fundam Clin Pharmacol 2003; 17(1): 1-10.
214. Petros A, Lamb G, Leone A, Moncada S, Bennett D, Vallance P. Effects of a nitric oxide synthase inhibitor in humans with septic shock. Cardiovasc Res 1994; 28(1): 34-9.
215. Rees DD. Role of nitric oxide in the vascular dysfunction of septic shock. Biochem Soc Trans 1995; 23(4): 1025-9.
216. Ashina M, Lassen LH, Bendtsen L, Jensen R, Olesen J. Effect of inhibition of nitric oxide synthase on chronic tension-type head-ache: a randomised crossover trial. Lancet 1999; 353(9149): 287-9.
217. Leiper J, Vallance P. Biological significance of endogenous methy-larginines that inhibit nitric oxide synthases. Cardiovasc Res 1999; 43(3): 542-8.
218. MacAllister RJ, Parry H, Kimoto M, et al. Regulation of nitric oxide synthesis by dimethylarginine dimethylaminohydrolase. Br J Pharmacol 1996; 119(8): 1533-40.
219. Murray-Rust J, Leiper J, McAlister M, et al. Structural insights into the hydrolysis of cellular nitric oxide synthase inhibitors by di-methylarginine dimethylaminohydrolase. Nat Struct Biol 2001; 8(8): 679-83.
220. Brenman JE, Christopherson KS, Craven SE, McGee AW, Bredt DS. Cloning and characterization of postsynaptic density 93, a ni-tric oxide synthase interacting protein. J Neurosci 1996; (23): 7407-15.
221. Fontana L, Souza AS, Del Bel EA, Oliveira RM. Ginkgo biloba leaf extract (EGb 761) enhances catalepsy induced by haloperidol and L-nitroarginine in mice. Braz J Med Biol Res 2005; 38(11): 1649-54.
222. Echeverry MB, Salgado ML, Ferreira FR, da-Silva CA, Del Bel EA. Intracerebroventricular administration of nitric oxide-sensitive guanylyl cyclase inhibitors induces catalepsy in mice. Psycho-pharmacology (Berl) 2007; 194(2): 271-8.
223. Seregélyes C, Igamberdiev AU, Maassen A, Hennig J, Dudits D, Hill RD. NO-degradation by alfalfa class 1 hemoglobin (Mhb1): a possible link to PR-1a gene expression in Mhb1-overproducing to-bacco plants. FEBS Lett 2004; 571(1-3): 61-6.
224. Lundblad M, Andersson M, Winkler C, Kirik D, Wierup N, Cenci MA. Pharmacological validation of behavioural measures of akine-sia and dyskinesia in a rat model of Parkinson's disease. Eur J Neu-rosci 2002; 15(1): 120-32.
225. Dekundy A, Lundblad M, Danysz W, Cenci MA. Modulation of L-DOPA-induced abnormal involuntary movements by clinically tested compounds: further validation of the rat dyskinesia model. Behav Brain Res 2007; 179(1): 76-89.
226. Lugnier C. Cyclic nucleotide phosphodiesterase (PDE) superfa-mily: a new target for the development of specific therapeutic agents. Pharmacol Ther 2006; 109(3): 366-98.
227. Menniti FS, Faraci WS, Schmidt CJ. Phosphodiesterases in the CNS: targets for drug development. Nat Rev Drug Discov 2006; 5(8): 660-70.
228. Schlossmann J, Hofmann F. CGMP-dependent protein kinases in drug discovery. Drug Discov Today 2005; 10(9): 627-34.